The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
<p><strong>Objective:</strong> Post hoc analysis of pooled data from 9 randomised controlled trials to assess the effect of tofacitinib (oral Janus kinase inhibitor for treatment of rheumatoid arthritis [RA] and psoriatic arthritis [PsA]) on residual pain in patients with RA or PsA...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022
|
| _version_ | 1797107858798542848 |
|---|---|
| author | Dougados, M Taylor, P Bingham III, CO Fallon, L Brault, Y Roychoudhury, S Wang, L Kessouri, M |
| author_facet | Dougados, M Taylor, P Bingham III, CO Fallon, L Brault, Y Roychoudhury, S Wang, L Kessouri, M |
| author_sort | Dougados, M |
| collection | OXFORD |
| description | <p><strong>Objective:</strong> Post hoc analysis of pooled data from 9 randomised controlled trials to assess the effect of tofacitinib (oral Janus kinase inhibitor for treatment of rheumatoid arthritis [RA] and psoriatic arthritis [PsA]) on residual pain in patients with RA or PsA with abrogated inflammation.</p>
<p><strong>Methods:</strong> Patients who received ≥1 dose of tofacitinib 5 mg twice daily (BID), adalimumab or placebo with/without background conventional synthetic disease-modifying antirheumatic drugs and had abrogated inflammation (swollen joint count [SJC]=0 and C reactive protein [CRP]<6 mg/L) after 3 months’ therapy were included. Assessments included Patient’s Assessment of Arthritis Pain at Month 3 (Visual Analogue Scale [VAS] 0–100 mm). Scores were summarised descriptively; treatment comparisons assessed by Bayesian network meta analyses (BNMA).</p>
<p><strong>Results:</strong> From the total RA/PsA population, 14.9% (382/2568), 17.1% (118/691) and 5.5% (50/909) of patients receiving tofacitinib, adalimumab and placebo, respectively, had abrogated inflammation after 3 months’ therapy. RA/PsA patients with abrogated inflammation receiving tofacitinib/adalimumab had higher baseline CRP versus placebo; RA patients receiving tofacitinib/adalimumab had lower SJC and longer disease duration versus placebo. Median residual pain (VAS) at Month 3 was 17.0, 19.0 and 33.5 in RA patients treated with tofacitinib, adalimumab or placebo, and 24.0, 21.0 and 27.0 in PsA patients, respectively. Residual pain reductions with tofacitinib/adalimumab versus placebo were less prominent in PsA versus RA patients, with no significant differences between tofacitinib/adalimumab, per BNMA.</p>
<p><strong>Conclusion:</strong> Patients with RA/PsA with abrogated inflammation receiving tofacitinib/adalimumab had greater residual pain reduction versus placebo at Month 3. Results were similar between tofacitinib/adalimumab.</p> |
| first_indexed | 2024-03-07T07:20:03Z |
| format | Journal article |
| id | oxford-uuid:97e1a651-d697-4668-bc2b-6c6e728d7590 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:20:03Z |
| publishDate | 2022 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:97e1a651-d697-4668-bc2b-6c6e728d75902022-10-03T09:15:38ZThe effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:97e1a651-d697-4668-bc2b-6c6e728d7590EnglishSymplectic ElementsBMJ Publishing Group2022Dougados, MTaylor, PBingham III, COFallon, LBrault, YRoychoudhury, SWang, LKessouri, M<p><strong>Objective:</strong> Post hoc analysis of pooled data from 9 randomised controlled trials to assess the effect of tofacitinib (oral Janus kinase inhibitor for treatment of rheumatoid arthritis [RA] and psoriatic arthritis [PsA]) on residual pain in patients with RA or PsA with abrogated inflammation.</p> <p><strong>Methods:</strong> Patients who received ≥1 dose of tofacitinib 5 mg twice daily (BID), adalimumab or placebo with/without background conventional synthetic disease-modifying antirheumatic drugs and had abrogated inflammation (swollen joint count [SJC]=0 and C reactive protein [CRP]<6 mg/L) after 3 months’ therapy were included. Assessments included Patient’s Assessment of Arthritis Pain at Month 3 (Visual Analogue Scale [VAS] 0–100 mm). Scores were summarised descriptively; treatment comparisons assessed by Bayesian network meta analyses (BNMA).</p> <p><strong>Results:</strong> From the total RA/PsA population, 14.9% (382/2568), 17.1% (118/691) and 5.5% (50/909) of patients receiving tofacitinib, adalimumab and placebo, respectively, had abrogated inflammation after 3 months’ therapy. RA/PsA patients with abrogated inflammation receiving tofacitinib/adalimumab had higher baseline CRP versus placebo; RA patients receiving tofacitinib/adalimumab had lower SJC and longer disease duration versus placebo. Median residual pain (VAS) at Month 3 was 17.0, 19.0 and 33.5 in RA patients treated with tofacitinib, adalimumab or placebo, and 24.0, 21.0 and 27.0 in PsA patients, respectively. Residual pain reductions with tofacitinib/adalimumab versus placebo were less prominent in PsA versus RA patients, with no significant differences between tofacitinib/adalimumab, per BNMA.</p> <p><strong>Conclusion:</strong> Patients with RA/PsA with abrogated inflammation receiving tofacitinib/adalimumab had greater residual pain reduction versus placebo at Month 3. Results were similar between tofacitinib/adalimumab.</p> |
| spellingShingle | Dougados, M Taylor, P Bingham III, CO Fallon, L Brault, Y Roychoudhury, S Wang, L Kessouri, M The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis |
| title | The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis |
| title_full | The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis |
| title_fullStr | The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis |
| title_full_unstemmed | The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis |
| title_short | The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis |
| title_sort | effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis |
| work_keys_str_mv | AT dougadosm theeffectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT taylorp theeffectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT binghamiiico theeffectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT fallonl theeffectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT braulty theeffectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT roychoudhurys theeffectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT wangl theeffectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT kessourim theeffectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT dougadosm effectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT taylorp effectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT binghamiiico effectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT fallonl effectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT braulty effectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT roychoudhurys effectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT wangl effectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis AT kessourim effectoftofacitinibonresidualpaininpatientswithrheumatoidarthritisandpsoriaticarthritis |